Mostrar el registro sencillo del ítem
dc.contributor.author
Rearte, Analía
dc.contributor.author
Castelli, Juan Manuel
dc.contributor.author
Rearte, Ramiro
dc.contributor.author
Fuentes, Nora Angéelica
dc.contributor.author
Pennini, Velen
dc.contributor.author
Pesce, Martina
dc.contributor.author
Barbeira, Pilar Barcena
dc.contributor.author
Iummato, Luciana Eva
dc.contributor.author
Laurora, Melisa
dc.contributor.author
Bartolomeu, María Lucía
dc.contributor.author
Galligani, Guido
dc.contributor.author
Del Valle Juarez, María
dc.contributor.author
Giovacchini, Carlos María
dc.contributor.author
Santoro, Adrián
dc.contributor.author
Esperatti, Mariano
dc.contributor.author
Tarragona, Sonia
dc.contributor.author
Vizzotti, Carla
dc.date.available
2022-07-21T18:02:37Z
dc.date.issued
2022-03
dc.identifier.citation
Rearte, Analía; Castelli, Juan Manuel; Rearte, Ramiro; Fuentes, Nora Angéelica; Pennini, Velen; et al.; Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study; Elsevier Science Inc.; Lancet; 399; 10331; 3-2022; 1254-1264
dc.identifier.issn
0140-6736
dc.identifier.uri
http://hdl.handle.net/11336/162837
dc.description.abstract
Background: In January, 2021, a vaccination campaign against COVID-19 was initiated with the rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines in Argentina. The objective of this study was to estimate vaccine effectiveness at reducing risk of SARS-CoV-2 infection and COVID-19 deaths in people older than 60 years. Methods: In this test-negative, case-control, and retrospective longitudinal study done in Argentina, we evaluated the effectiveness of three vaccines (rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV) on SARS-CoV-2 infection and risk of death in people with RT-PCR confirmed COVID-19, using data from the National Surveillance System (SNVS 2.0). All individuals aged 60 years or older reported to SNVS 2.0 as being suspected to have COVID-19 who had disease status confirmed with RT-PCR were included in the study. Unvaccinated individuals could participate in any of the analyses. People with suspected COVID-19 who developed symptoms before the start of the implementation of the vaccination programme for their age group or district were excluded from the study. The odds ratio of SARS-CoV-2 infection was evaluated by logistic regression and the risk of death in individuals with RT-PCR confirmed COVID-19 was evaluated by proportional hazard regression models, adjusted for possible confounders: age at the time of the symptom onset date, sex, district of residence, epidemiological week corresponding to the symptom onset date, and history of COVID-19. The estimation of vaccine effectiveness to prevent death due to COVID-19 was done indirectly by combining infection and death estimates. In addition, we evaluated the effect of the first dose of viral vector vaccines across time. Findings: From Jan 31, to Sept 14, 2021, 1 282 928 individuals were included, of whom 687 167 (53·6%) were in the rAd26-rAd5 analysis, 358 431 (27·6%) in the ChAdOx1 nCoV-19 analysis, and 237 330 (18·5%) in the BBIBP-CorV analysis. Vaccine effectiveness after two doses was high for all three vaccines, adjusted odds ratio 0·36 (95% CI 0·35–0·37) for rAd26-rAd5, 0·32 (0·31–0·33) for ChAdOx1 nCoV-19, and 0·56 (0·55–0·58) for BBIBP-CorV. After two doses, the effect on deaths was higher than that on risk of infection: adjusted hazard ratio 0·19 (95% CI 0·18–0·21) for rAd26-rAd5, 0·20 (0·18–0·22) for ChAdOx1 nCoV-19, and 0·27 (0·25–0·29) for BBIBP-CorV. The indirectly estimated effectiveness on deaths was 93·1% (95% CI 92·6–93·5) for rAd26-rAd5, 93·7% (93·2–94·3) for ChAdOx1 nCoV-19, and 85·0% (84·0–86·0) for BBIBP-CorV following two doses. First dose effect of viral vector vaccines remained stable over time. Interpretation: The vaccines used in Argentina showed effectiveness in reducing infection and death by SARS-CoV-2 and COVID-19. Funding: None.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Elsevier Science Inc.
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
COVID-19
dc.subject
VACCINES
dc.subject
EFFECTIVINESS
dc.subject.classification
Epidemiología
dc.subject.classification
Ciencias de la Salud
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2022-07-21T15:58:55Z
dc.journal.volume
399
dc.journal.number
10331
dc.journal.pagination
1254-1264
dc.journal.pais
Estados Unidos
dc.journal.ciudad
Amsterdam
dc.description.fil
Fil: Rearte, Analía. Ministerio de Salud de la Nación; Argentina
dc.description.fil
Fil: Castelli, Juan Manuel. Ministerio de Salud de la Nación; Argentina
dc.description.fil
Fil: Rearte, Ramiro. Universidad Nacional de La Plata. Facultad de Ciencias Veterinarias. Departamento de Ciencias Básicas. Cátedra de Fisiología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina
dc.description.fil
Fil: Fuentes, Nora Angéelica. Universidad Nacional de Mar del Plata; Argentina
dc.description.fil
Fil: Pennini, Velen. Ministerio de Salud de la Nación; Argentina
dc.description.fil
Fil: Pesce, Martina. Ministerio de Salud de la Nación; Argentina
dc.description.fil
Fil: Barbeira, Pilar Barcena. Ministerio de Salud de la Nación; Argentina
dc.description.fil
Fil: Iummato, Luciana Eva. Ministerio de Salud de la Nación; Argentina
dc.description.fil
Fil: Laurora, Melisa. Ministerio de Salud de la Nación; Argentina
dc.description.fil
Fil: Bartolomeu, María Lucía. Ministerio de Salud de la Nación; Argentina
dc.description.fil
Fil: Galligani, Guido. Ministerio de Salud de la Nación; Argentina
dc.description.fil
Fil: Del Valle Juarez, María. Ministerio de Salud de la Nación; Argentina
dc.description.fil
Fil: Giovacchini, Carlos María. Ministerio de Salud de la Nación; Argentina
dc.description.fil
Fil: Santoro, Adrián. Ministerio de Salud de la Nación; Argentina
dc.description.fil
Fil: Esperatti, Mariano. Universidad Nacional de Mar del Plata; Argentina
dc.description.fil
Fil: Tarragona, Sonia. Universidad Nacional de Mar del Plata; Argentina
dc.description.fil
Fil: Vizzotti, Carla. Universidad Nacional de Mar del Plata; Argentina
dc.journal.title
Lancet
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/S0140-6736(22)00011-3
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0140673622000113
Archivos asociados